Allarity Therapeutics, Inc. announced the results of a prospective Phase 2 clinical study of the Company's proprietary DRP® technology that will be presented in a poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023. In the Phase 1/2 study, researchers analyzed the transcriptomic profiles of 37 evaluable metastatic breast cancer (mBC) patients and, based on analysis of biomarkers comprised within a DRP® signature, assigned response likelihood scores (DRP® 0-100) of patient tumors to a targeted, liposomal form of cisplatin (LiPlaCis™). Data from the poster presentation will show that the entcisplatin-DRP® identified all four mBC patients who demonstrated a partial response (PR) in the trial as likely responders to the LiPlaCis™ treatment regimen using a DRP80+ score as a cut-off for likely responders.

In addition, the cisplatin-DRP® also identified mBC patients demonstrating other efficacy signals, including improved progression-free survival. Based on these data, researchers concluded that the cisplatin-DRP® companion diagnostic can differiate, in a statistically significant way, clinical responders and non-responders to cisplatin administered as LiPlaCis™. sing a proprietary systems biology algorithm, Allarity's DRP® technology analyzes transcriptomic differences between cell lines that are sensitive and resistant to provide a biomarker signature of drug response and resistance.

The DRP® platform further refines the predictive signature through a clinical relevance filter (created from more than 3,000 actual tumor biopsy samples from a broad range of cancer drug clinical trials) to eliminate unnecessary biomarkers. By remaining agnostic to what influences tumor response or resistance to a drug, DRP® enables the identification of unknown biomarkers crucial to drug response or resistance. Allarity conducted the study in collaboration with investigators at hospitals in Denmark and its CRO Smerud Medical Research International AS.

The LiPlaCis™ program is currently licensed to CHOSA Oncology AB for further clinical development.